

MISSISSIPPI DIVISION OF MEDICAID

Pharmacy & Therapeutics Committee

Table 100 / Flowood, MS

February 18, 2025

10:00am to 2:00pm

AGENDA

- I. Call to Order
- II. Welcome & Introductions
- III. Administrative Matters
- IV. Approval of October 22, 2024 Meeting Minutes
- V. PDL Compliance/Generic Percent Report Updates
- VI. Public Comment
- VII. New Drug/New Generic Reviews
 1. **Androgenic Agents:** Undecatrex (testosterone undecanoate) – *Financial Review Only*
Azmiro (testosterone cypionate) - Financial Review Only
 2. **Angiotensin Modulators (ARB Combinations):** sacubitril-valsartan - *Financial Review Only*
 3. **Anticonvulsants (Adjuvants):** oxcarbazepine ER tablet – *Financial Review Only*
 4. **Antiparkinson’s Agents (Injectable):** Vyalev (foscarbidopa/foslevodopa)
 5. **Antipsychotics, Injectable (Atypicals):** Erzofri (paliperidone) – *Financial Review Only*
 6. **Antipsychotics, Oral:** Cobenfy (xanomeline/trospium)
Opipza (aripiprazole) – *Financial Review Only*
 7. **Atopic Dermatitis:** Ebglyss (lebrikuzmab-lbkz)
 8. **Bronchodilators, Beta Agonist (Inhalation Solution):** formoterol fumarate – *Financial Review Only*
 9. **Calcium Channel Blockers (Short Acting):** nimodipine solution – *Financial Review Only*
 10. **Cytokine & CAM Antagonists:** Nemluvio (nemolizumab-ilto)
Tremfya (guselkumab) - *Financial Review Only*
Yuflyma CF (adalimuab-aaty) – *Financial Review Only*
 11. **Factor Deficiency Products (Other Hemophilia Products):** Hympavizi (marstacimab-hncq)
 12. **Hypoglycemics (DPP4s and Combinations):** Zitumev (sitagliptin/metformin) – *Financial Review Only*
Zitumev XR (sitagliptin/metformin) – *Financial Review Only*
 13. **Hypoglycemics (Incretin Mimetics/Enhancers):** exenatide – *Financial Review Only*

14. **Miscellaneous Brand/Generic (Epinephrine):** Neffy (epinephrine) – *Financial Review Only*
15. **Multiple Sclerosis Agents:** Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) – *Financial Review Only*
16. **Muscular Dystrophy Agents:** Duvyzat (givinostat)
17. **NSAIDs:** Dolobid (diflunisal) – *Financial Review Only*
18. **Opiate Dependence Treatments (Dependence):** lofexidine – *Financial Review Only*
19. **Parathyroid Agents:** Yorvipath (palopegteriparatide)
20. **Select Contraceptive Products (Oral Contraceptives):** Femlyv ODT (ethinyl estradiol and norethindrone acetate) – *Financial Review Only*
21. **Stimulants and Related Agents (Non-Stimulants):** Onyda XR (clonidine) suspension – *Financial Review Only*

VIII. Other Business

IX. Division of Medicaid Update

X. Remaining 2025 Meeting Dates

1. Tuesday, May 13, 2025
2. Tuesday, August 12, 2025
3. Tuesday, October 21, 2025